| Literature DB >> 30222732 |
Arthur Mpimbaza1, Andrew Walakira2, Grace Ndeezi3, Anne Katahoire1, Charles Karamagi3,4, Samuel L Nsobya2, Stephen Tukwasibwe2, Victor Asua2, Philip J Rosenthal5.
Abstract
BACKGROUND: Evidence for association between sickle cell and alpha thalassemia trait and severe malaria is compelling. However, for these polymorphisms associations with uncomplicated malaria, and for G6PD deficiency associations with uncomplicated and severe malaria, findings have been inconsistent. We studied samples from a three-arm case-control study with the objective of determining associations between common host erythrocyte polymorphisms and both uncomplicated and severe malaria, including different severe malaria phenotypes.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30222732 PMCID: PMC6141089 DOI: 10.1371/journal.pone.0203229
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Study profile.
Characteristics of the study population.
| Variable | Community | Uncomplicated malaria controls | Severe malaria | p-value | p-value | p-value | |
|---|---|---|---|---|---|---|---|
| Age in years (IQR) | 2.15 (1.35–3.17) | 2.13 (1.34–3.15) | 1.98 (1.11–2.95) | 0.449 | <0.001 | <0.001 | |
| Age category | < 1year | 44 (13.5%) | 46 (14.1%) | 65 (20.0%) | 0.926 | <0.001 | <0.001 |
| 1 to < 3 years | 183 (56.3%) | 184 (56.6%) | 181 (55.6%) | ||||
| 3 to < 5 years | 78 (24.0%) | 70 (21.5%) | 57 (17.5%) | ||||
| 5 years or more | 20 (6.1%) | 25 (7.6%) | 22 (6.7%) | ||||
| Females, n (%) | 174 (53.7%) | 157 (48.4%) | 152 (46.7%) | 0.172 | 0.07 | 0.624 | |
| Ethnicity (Nilotic versus Bantu) | 15 (4.6%) | 17 (5.2%) | 11 (3.4%) | 0.723 | 0.393 | 0.200 | |
a Community controls vs. uncomplicated malaria controls
b community controls vs. severe malaria
c uncomplicated malaria controls vs. severe malaria.
Genotype and allele frequencies for specified gene polymorphism among cases and controls.
| Variable | Genotype | Community controls | Uncomplicated malaria controls | Severe malaria cases | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Number | Prevalence | Allele frequency | Number | Prevalence | Allele frequency | Number tested | Prevalence | Allele frequency | ||
| HbAS | AA | 317 (97.5%) | 275 (86.7%) | 6.6% | 314(96.6%) | 282 (89.8%) | 5.8% | 314 (96.6%) | 297 (94.5%) | 3.1% |
| AS | 42 (13.2%) | 27 (8.6%) | 14 (4.4%) | |||||||
| SS | 0 | 5 (1.5%) | 3 (0.9%) | |||||||
| HbAC | AA | 320 (97.5%) | 0 | 0 | 316 (96.3%) | 0 | 0 | 317 (96.6%) | 0 | 0 |
| AC | 0 | 0 | 0 | |||||||
| CC | 0 | 0 | 0 | |||||||
| α-thalassemia | αα/αα | 304 (93.5%) | 184 (60.5%) | 22.3% | 300 (92.3%) | 167 (55.6%) | 27.3% | 302 (92.9%) | 223 (73.8%) | 15.6% |
| _ α/αα | 104 (34.2%) | 102 (34.0%) | 64 (21.1%) | |||||||
| _α/_α | 16 (5.2%) | 31 (10.3%) | 15 (4.9%) | |||||||
| G6PD-females | Wild type | 172 (98.8%) | 147 (85.4%) | 8.7% | 118 (78.1%) | 13.2% | 113 (76.3%) | 13.5% | ||
| Heterozygous | 20 (11.6%) | 26 (17.2%) | 30 (20.2%) | |||||||
| Homozygous | 5 (2.9%) | 7 (4.6%) | 5 (3.3%) | |||||||
| G6PD-males | Wild type | 142 (94.6%) | 122 (85.9%) | 7.5% | 132 (81.4%) | 18.5% | 166 (95.9%) | 140 (84.3%) | 15.6% | |
| Hemizygous | 20 (14.0%) | 30 (18.5%) | 26 (15.6%) | |||||||
Association between specific host polymorphisms and risk of malaria infection and severe malaria.
| Host polymorphism | Prevalence n/N (%) | Adjusted analysis | ||||
|---|---|---|---|---|---|---|
| Community controls | Uncomplicated malaria | Severe malaria | Uncomplicated malaria | Severe malaria cases | Severe malaria cases | |
| OR (95%CI); p-value | OR (95%CI); p-value | OR (95%CI); p-value | ||||
| AS | 42/317 (13.2%) | 27/309 (8.7%) | 14/311 (4.5%) | 0.60 (0.34, 1.03); 0.065 | 0.46 (0.23, 0.95); 0.036 | 0.23 (0.11, 0.50); <0.001 |
| _α/αα | 104/304 (34.2%) | 102/300 (34.0%) | 64/302 (21.1%) | 1.11 (0.74, 1.56); 0.697 | 0.51 (0.24, 0.77); 0.001 | 0.49 (0.32, 0.76); 0.002 |
| _α/_α | 16/304 (5.2%) | 31/300 (10.3%) | 15/302 (4.9%) | 2.40 (1.15, 5.03); 0.020 | 0.34 (0.16, 0.73); 0.005 | 1.03 (0.46, 2.27);0.935 |
| G6PD-Females Heterozygous A/A- | 20/172 (11.6%) | 26/151 (17.2%) | 30/148 (20.2%) | 1.43 (0.65, 3.14); 0.370 | 1.98 (0.78, 5.03); 0.150 | 1.94 (0.75, 4.99); 0.169 |
| G6PD-Females Homozygous A-/A- | 5/172 (2.9%) | 7/151 (4.6%) | 5/148 (3.3%) | 3.21 (0.28, 35.7); 0.341 | 0.42 (0.07, 2.64); 0.350 | 1.16 (0.25, 5.40); 0.847 |
| G6PD Males Hemizygote A- | 20/142 (14.0%) | 30/162 (18.5%) | 26/166 (15.6%) | 1.52 (0.67, 3.41); 0.307 | 0.99 (0.40, 2.42); 0.986 | 0.86 (0.35, 2.08);0.745 |
| AS | 18/135 (13.3%) | 11/132 (8.3%) | 6/130 (4.6%) | NA | 0.47 (0.13, 1.65); 0.245 | 0.17 (0.04, 0.65); 0.009 |
| _α/αα | 36/129 (27.9%) | 45/124 (36.2%) | 33/128 (25.7%) | NA | 0.66 (0.35, 1.23); 0.193 | 0.78 (0.38, 1.57); 0.487 |
| _α/_α | 6/129 (4.6%) | 13/124 (10.4%) | 10/128 (7.8%) | NA | 0.55(0.21, 1.44); 0.226 | 1.60 (0.51, 5.03); 0.415 |
| G6PD-Females Heterozygous A/A- | 7/72 (9.7%) | 12/64 (18.7%) | 11/67 (16.4%) | NA | 1.91 (0.45, 7.99); 0.372 | 0.83 (0.15, 4.40); 0.835 |
| G6PD-Females Homozygous A-/A- | 3/72 (4.1%) | 5/64 (7.8%) | 2/67 (2.9%) | NA | 0.22 (0.02, 2.39); 0.218 | 0.29 (0.001, 96.1); 0.678 |
| G6PD Males Hemizygote A- | 9/61 (14.7%) | 10/68 (14.7%) | 10/66 (15.1%) | NA | 3.24 (0.56, 21.2); 0.179 | 0.25 (0.02, 2.42); 0.233 |
| AS | 7/84 (8.3%) | 4/83 (4.8%) | 6/84 (7.1%) | NA | 1.34 (0.37, 4.83); 0.647 | 0.80 (0.24, 2.66); 0.724 |
| _α/αα | 34/80 (42.5%) | 26/80 (32.5%) | 13/79 (16.4%) | NA | 0.31 (0.12, 0.80); 0.016 | 0.24 (0.09, 0.59); 0.002 |
| _α/_α | 7/80 (8.7%) | 10/80 (12.5%) | 2/79 (2.5%) | NA | 0.08 (0.009, 0.72); 0.025 | 0.47 (0.08, 2.63); 0.396 |
| G6PD-Females Heterozygous A/A- | 2/44 (4.5%) | 7/39 (17.9%) | 6/35 (17.1%) | NA | ||
| G6PD-Females Homozygous A-/A- | 1/44 (2.2%) | 1/39 (2.5%) | 0 | NA | ||
| G6PD Males Hemizygote A- | 5/40 (12.5%) | 11/45 (24.4%) | 9/48 (18.7%) | NA | 0.37 (0.05, 2.41); 0.305 | 1.21 (0.29, 5.02); 0.784 |
NA: Not applicable
a Adjusted analysis: uncomplicated malaria cases vs. community controls
b Adjusted analysis: severe malaria cases vs. uncomplicated malaria controls
cAdjusted analysis: severe malaria cases vs. community controls
d Analysis limited to case control pairs; cases are defined by the listed severe malaria phenotype
eInsufficient numbers resulting in unintelligible effect estimates and confidence intervals
Association between α-thalassemia heterozygote (_α/αα) and Hemoglobin AS including interaction terms.
| Variables | Odds Ratio (95%CI) | p-value |
|---|---|---|
| Normal (HbAA and αα/αα) | ||
| HbAA and _α/αα | 0.45 (0.29, 0.70) | <0.001 |
| HbAS and αα/αα | 0.28 (0.10, 0.76) | 0.013 |
| HbAS and _α/αα | 0.45 (0.11, 1.84) | 0.269 |
| Normal (HbAA and αα/αα) | Ref | 1 |
| HbAA and _α/αα | 2.18 (1.41, 3.38) | <0.001 |
| HbAS and αα/αα | 3.47 (1.30, 9.27) | 0.013 |
| HbAS and _α/αα | 2.19 (0.54, 8.89) | 0.269 |
| Hemoglobin S heterozygote (HbAS) | 0.28 (0.10, 0.76) | 0.013 |
| α-thalassemia heterozygote (_α/αα) | 0.45 (0.29, 0.70) | <0.001 |
| HbAS | 3.45 (0.57, 20.7) | 0.175 |
Measures of interaction on an additive scale (based on Model B)
Relative excess risk due to interaction: -2.07 (95% CI, -6.40, 2.24)
Attributable proportion due to interaction: -0.84 (95% CI -3.42, 1.73)
Synergy index: 0.41 (95% CI 0.04, 3.88)
a Interaction term of HbAS and _α/αα
#: Operator symbol for creating an interaction between two variables.